Silence Therapeutics plc (SLN)

NGM – Real Time Price. Currency in USD

14.68

-0.04 (-0.27%)

Market open: Aug 12, 2026, 10:16 AM EDT

14.75

+0.03 (0.20%)

Previous after-hours: Aug 11, 2026, 7:53 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

09.08.2026

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow, Monday, August 10, 2026 at 8:00 a.m. EDT. Investor Webcast & Conference Call Information Conference call link: https://register-conf.media-server.com/register/BI4a60039edc0.

Videos

No Data

There is no data to display

Silence Therapeutics plc (SLN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Silence Therapeutics plc (SLN)

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Videos

No Data

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Videos

No Data

Search stocks

Silence Therapeutics plc (SLN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Silence Therapeutics plc (SLN)

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Videos

No Data

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Videos

No Data